CompletedPhase 1

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

United Kingdom18 participantsStarted 2012-08

Plain-language summary

The purpose of this study is to look at drug levels of AZD5423 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with four different devices), to healthy subjects

Who can participate

Age range18 Years – 45 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy male or women of non-childbearing potential aged 18-45 years inclusive with suitable veins for cannulation or repeated vein puncture * Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive and rounding allowed) and weight between 50 and 100 kg (inclusive) * Be able to inhale from the inhaler devices used in the study according to given instructions as well as be able to perform spirometry Exclusion Criteria: * History of any clinically significant disease or disorder * Current smokers * Any clinically relevant abnormal findings

What they're measuring

Pharmacokinetics of AZD5423 delivered by the new dry powder inhaler in terms of: Fpulmonary

Timeframe: Blood samples taken pre-dose and at10, 20 and 40 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48 and 96 hours post dose.

Trial details

NCT IDNCT01635985

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Bioavailability and AUC trials